Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 53 of 11968 for:    Oral Cancer

PK Analysis of Antitumor B in Patients With Oral Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03459729
Recruitment Status : Not yet recruiting
First Posted : March 9, 2018
Last Update Posted : October 10, 2019
Sponsor:
Information provided by (Responsible Party):
Stuart Wong, Medical College of Wisconsin

Brief Summary:
A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the "window" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic effects of an agent; in this study pharmacokinetic properties will be examined.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Oral Cavity Drug: Antitumor B Phase 1

Detailed Description:

Study Intervention Description:

Study participants will take the natural botanical compound ATB during a short window (7 to 28 days). Participants will provide blood samples, and saliva samples during ATB administration and a portion of the initial tumor biopsy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: PK Analysis of Antitumor B in Patients With Oral Cancer
Estimated Study Start Date : December 1, 2019
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oral Cancer

Arm Intervention/treatment
Experimental: Antitumor B
ATB will be administered on an outpatient basis.
Drug: Antitumor B
Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).
Other Names:
  • Zeng Sheng Ping
  • ATB
  • ACAPHA




Primary Outcome Measures :
  1. Area under the Curve for Saliva [ Time Frame: 30, 60, 120, 180, 240, 360, 480, and 1,440 min on Day 1 ]
    The AUC will be calculated using software. The calculation will be mg/ml X hour.

  2. Area under the Curve for Plasma [ Time Frame: 30, 60, 120, 180, 240, 360, 480, and 1,440 min on Day 1 ]
    The AUC will be calculated using software. The calculation will be mg/ml X hour.

  3. Cmax for Saliva [ Time Frame: 30, 60, 120, 180, 240, 360, 480, and 1,440 min on Day 1 ]
    The Cmax will be calculated using software. The calculation will be ng/ml.

  4. Cmax for Plasma [ Time Frame: 30, 60, 120, 180, 240, 360, 480, and 1,440 min on Day 1 ]
    The Cmax will be calculated using software. The calculation will be ng/ml.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of oral cavity squamous cell cancer.
  • Patient can start study agent administration but histological confirmation of squamous cell cancer (SCC) of the oral cavity (or histologic variants of SCC) by the pathologist must happen within 7 days of registration in order to continue study agent administration.
  • Clinical stage II-IVA (as defined by the AJCC, 8th Edition) and amenable to surgical resection
  • New diagnosis of oral SCC, new second primary, or recurrent oral SCC following a minimum remission of 6 months following previous definite surgery
  • History and physical examination by an otolaryngologist and medical oncologist within 14 calendar days of study registration
  • Study agent administration should start within 7 days of registration
  • Patient must receive administration of study agent for a minimum of 7 days
  • Zubrod/ECOG Performance status < 2.
  • Age ≥ 18 years.
  • CBC/differential obtained within 14 calendar days prior to registration, with adequate bone marrow function defined as follows:

    • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
    • Platelets ≥ 100,000 cells/mm3;
    • Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.);
  • Adequate renal and hepatic function within 14 calendar days prior to registration, defined as follows:

    o Serum creatinine < 1.5 mg/dl or creatinine clearance (CCr) ≥ 50 ml/min within 14 calendar days prior to registration, determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = [(140 - age) x (wt in kg)] [(Serum Cr mg/dl) x (72)] CCr female = 0.85 x (CrCl male)

  • Total bilirubin < 2 x the institutional ULN within 14 calendar days prior to registration
  • AST or ALT ≤ 3 x the institutional ULN within 14 calendar days prior to registration
  • Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior to registration, with the following required parameters:

    • Magnesium: > 0.9 mg/dl or < 3 mg/dl;
    • Calcium: > 7 mg/dl or < 12.5 mg/dl;
    • Glucose: > 40 mg/dl or < 250 mg/dl;
    • Potassium: > 3 mmol/L or < 6 mmol/L;
    • Sodium: > 130 mmol/L or < 155 mmol/L.
  • Female patients must meet one of the following:

    • Postmenopausal for at least one year before the screening visit, or
    • Surgically sterile (i.e. undergone a hysterectomy or bilateral oophorectomy), or
    • If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agree to practice two acceptable methods of contraception (combination methods requires use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 90 days after the last dose of study agent, AND
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)
  • Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:

    • Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR
    • Must also adhere to the guidelines of any study-specific pregnancy prevention program, if applicable, OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable methods of contraception.)
  • Patients must be deemed able to comply with the study plan.
  • Gastric tube study agent administration is permissible.
  • Patients must provide study-specific informed consent prior to study entry.

Exclusion Criteria:

  • History of active liver disease
  • Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or fetus.
  • Concurrent use of any medicinal botanical, natural, or other herbal compound/s that the study PI believes could potentially impact the results/objectives of this study
  • Planned subtotal or debulking surgery, as determined by enrolling physician determination, is not permissible.
  • Prior systemic chemotherapy for oral SCC; note that prior chemotherapy for a different cancer is allowable.
  • Prior radiotherapy for oral SCC is permissible if disease free for 1 year since prior oral cancer treatment and free of significant late radiation effects.
  • Severe active comorbidity such as uncontrolled cardiac disease, infection, severe COPD.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03459729


Contacts
Layout table for location contacts
Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office 414-805-8900 cccto@mcw.edu

Locations
Layout table for location information
United States, Wisconsin
Froedtert Hospital and the Medical College of Wisconsin Not yet recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Cancer Center Clinical Trials Office    866-680-0505 ext 8900    cccto@mcw.edu   
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: Stuart Wong, MD Medical College of Wisconsin

Layout table for additonal information
Responsible Party: Stuart Wong, Professor, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT03459729     History of Changes
Other Study ID Numbers: IIT-WONG-ATB
First Posted: March 9, 2018    Key Record Dates
Last Update Posted: October 10, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Stuart Wong, Medical College of Wisconsin:
Anti-tumor B
ACAPHA
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Mouth Neoplasms
Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Mouth Diseases
Stomatognathic Diseases